Sun Starts Integration Of GSK's Opiates Business
This article was originally published in Scrip
Sun Pharmaceutical Industries has started the integration of its opiates business in Australia, acquired earlier this year from GlaxoSmithKline, following the completion of the deal.
You may also be interested in...
Partner Therapeutics takes on Sanofi's immunostimulant. Novartis transitions struggling Arzerra for compassionate use only outside the US, with compensation to Genmab, while Shire licenses I.V. immunoglobulin candidate from AB Biosciences.
Industry leaders including Sanofi's ex-CEO and the chiefs of Sun, Lupin, Glenmark, Dr Reddy’s and Cipla discuss how India could leapfrog its pharma R&D efforts. Could the South Korea model or a hybrid approach including bringing back top talent bolster the country’s efforts to emerge as a global innovation hot spot?
FDA officials outline the impact of using alternative tools to assess manufacturing facilities amid COVID-19 and share key experiences around these, including with remote interactive evaluations.